What is the role of medical therapy in adrenal-dependent Cushing’s syndrome?

Cushing's syndrome

Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777 · see citing works

Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors

Fassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0467 · Cited by 1,566 · see citing works

Cushing's syndrome

Newell-Price, J. D. C., BERTAGNA, X. Y., Grossman, A. B., & Nieman, L. K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68699-6 · Cited by 1,220 · see citing works

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome

Fleseriu, M., Biller, B. M. K., Findling, J. W., Molitch, M. E., Schteingart, D. E., Gross, C., on behalf of the SEISMIC Study Investigators, The SEISMIC Study Investigators include, Auchus, R., Bailey, T., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3350 · Cited by 479 · see citing works

The Treatment of Cushing's Disease

Pivonello, R., Leo, M. D., Cozzolino, A., & Colao, A. A. L. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 471 · see citing works

Ketoconazole blocks testosterone synthesis

Pont, A. (1982) · Archives of Internal Medicine · doi:10.1001/archinte.142.12.2137 · Cited by 351 · see citing works

Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome

Verhelst, J. A., Trainer, P. J., Howlett, T. A., Perry, L., Rees, L. H., Grossman, A. B., Wass, J. A. H., & Sesser, G. M. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb03517.x · Cited by 308 · see citing works

Ketoconazole Blocks Testosterone Synthesis

Pont, A. (1982) · Archives of Internal Medicine · doi:10.1001/archinte.1982.00340250097015 · Cited by 297 · see citing works

Ketoconazole in Cushing's disease: is it worth a try?

Castinetti, F., Guignat, L., Giraud, P., Muller, M., Kamenicky, P., Drui, D., Caron, P., Luca, F., Donadille, B., Vantyghem, M. C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3628 · Cited by 285 · see citing works

Effectiveness of metyrapone in treating Cushing's syndrome: a retrospective multicenter study in 195 patients

Daniel, E., Aylwin, S., Mustafa, O., Ball, S., Munir, A., Boelaert, K., Chortis, V., Cuthbertson, D. J., Daousi, C., Rajeev, S. P., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2616 · Cited by 231 · see citing works

Clinical Pharmacokinetics of Ketoconazole

Daneshmend, T. K., & Warnock, D. W. (1988) · Clinical Pharmacokinetics · doi:10.2165/00003088-198814010-00002 · Cited by 230 · see citing works

Epidemiology of Cushing’s Syndrome

Steffensen, C., Bak, A. M., Rubeck, K. Z., & Jørgensen, J. O. L. (2010) · Neuroendocrinology · doi:10.1159/000314297 · Cited by 218 · see citing works

LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study

BERTAGNA, X. Y., Pivonello, R., Fleseriu, M., Zhang, Y., Robinson, P., Taylor, A. E., Watson, C. E., Maldonado, M., Hamrahian, A. H., Boscaro, M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2117 · Cited by 188 · see citing works

Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center

Baudry, C., Coste, J., Bou Khalil, R., Silvera, S., Guignat, L., Guibourdenche, J., Abbas, H., Legmann, P., Bertagna, X., & Bertherat, J. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0358 · Cited by 187 · see citing works

THERAPY IN ENDOCRINE DISEASE: Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review

Preda, V. A., Sen, J., Karavitaki, N., & Grossman, A. B. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0274 · Cited by 170 · see citing works

Metyrapone in long-term management of Cushing's disease.

Jeffcoate, W. J., REES, L. H., Tomlin, S., Jones, A. E., Edwards, C., & BESSER, G. M. (1977) · BMJ · doi:10.1136/bmj.2.6081.215 · Cited by 164 · see citing works

Advances in the medical treatment of Cushing's syndrome

Feelders, R. A., Newell-Price, J. D. C., Pivonello, R., Nieman, L. K., Hofland, L. J., & Lacroix, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30155-4 · Cited by 160 · see citing works

Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects

SCHULTE, H. M., BENKER, G., REINWEIN, D., SIPPELL, W. G., & ALLOLIO, B. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-5-1426 · Cited by 156 · see citing works

Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease

Fleseriu, M., Pivonello, R., Young, J., Hamrahian, A. H., Molitch, M. E., Shimizu, C., Tanaka, T., Shimatsu, A., White, T. A., Hilliard, A., et al. (2015) · Pituitary · doi:10.1007/s11102-015-0692-z · Cited by 155 · see citing works

Adrenal function after adrenalectomy for subclinical hypercortisolism and Cushing’s syndrome: a systematic review of the literature

Di Dalmazi, G., Berr, C. M., Fassnacht, M., Beuschlein, F., & Reincke, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1401 · Cited by 139 · see citing works

Mifepristone (RU 486) in Cushing's syndrome.

Johanssen, S., & Allolio, B. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0458 · Cited by 134 · see citing works

Sustained Remission of Cushing's Disease with Mitotane and Pituitary Irradiation

SCHTEINGART, D. E., TSAO, H. S., TAYLOR, C. I., MCKENZIE, A., VICTORIA, R., & THERRIEN, B. A. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-92-5-613 · Cited by 131 · see citing works

Subclinical hypercortisolism: a state, a syndrome, or a disease?

Dalmazi, G. D., Pasquali, R., Beuschlein, F., & Reincke, M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0272 · Cited by 124 · see citing works

Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial

Fleseriu, M., Pivonello, R., Elenkova, A., Salvatori, R., Auchus, R. J., Feelders, R. A., Geer, E. B., Greenman, Y., Witek, P., Cohen, F., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30313-4 · Cited by 101 · see citing works

Resetting the Abnormal Circadian Cortisol Rhythm in Adrenal Incidentaloma Patients With Mild Autonomous Cortisol Secretion

Debono, M., Harrison, R. F., Chadarevian, R., Gueroult, C., Abitbol, J.-L., & Newell-Price, J. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00823 · Cited by 100 · see citing works

A genetic and molecular update on adrenocortical causes of Cushing syndrome

Lodish, M. B., & Stratakis, C. A. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.24 · Cited by 88 · see citing works

Updates on the role of adrenal steroidogenesis inhibitors in Cushing’s syndrome: a focus on novel therapies

Fleseriu, M., & Castinetti, F. (2016) · Pituitary · doi:10.1007/s11102-016-0742-1 · Cited by 87 · see citing works

An analysis of different therapeutic options in patients with C ushing's syndrome due to bilateral macronodular adrenal hyperplasia: a single‐centre experience

Albiger, N. M., Ceccato, F., Zilio, M., Barbot, M., Occhi, G., Rizzati, S., Fassina, A., Mantero, F., Boscaro, M., Iacobone, M., et al. (2015) · Clinical Endocrinology · doi:10.1111/cen.12763 · Cited by 83 · see citing works

Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist

Hunt, H., Belanoff, J. K., Walters, I. A. S., Gourdet, B., Thomas, J. A., Barton, N., Unitt, J. F., Phillips, T., Swift, D., & Eaton, E. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00162 · Cited by 69 · see citing works

Metyrapone treatment in Cushing’s syndrome: a real-life study

Ceccato, F., Zilio, M., Barbot, M., Albiger, N. M. E., Antonelli, G., Plebani, M., Watutantrige‐Fernando, S., Sabbadin, C., Boscaro, M., & Scaroni, C. M. (2018) · Endocrine · doi:10.1007/s12020-018-1675-4 · Cited by 69 · see citing works

Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double‐Blind, Randomized, Placebo‐Controlled Phase 1 Clinical Study

Hunt, H., Donaldson, K. M., Strem, M., Zann, V., Leung, P. M., Sweet, S., Connor, A. L., Combs, D., & Belanoff, J. K. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.389 · Cited by 66 · see citing works

INHIBITION OF ALDOSTERONE SECRETION AND MODIFICATION OF ELECTROLYTE EXCRETION IN MAN BY A CHEMICAL INHIBITOR OF 11β-HYDROXYLATION*†

Coppage, W. S., Island, D. P., Smith, M. A., & Liddle, G. W. (1959) · Journal of Clinical Investigation · doi:10.1172/jci103988 · Cited by 65 · see citing works

Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in cushing's syndrome

Allolio, B., Schulte, H. M., Kaulen, D., Reincke, M., Jaursch-Hancke, C., & Winkelmann, W. (1988) · Journal of Molecular Medicine · doi:10.1007/bf01735795 · Cited by 64 · see citing works

Preoperative medical treatment in Cushing’s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN

Valassi, E., Franz, H., Brue, T. C., Feelders, R. A., Netea-Maier, R. T., Tsagarakis, S., Webb, S. M., Yaneva, M., Reincke, M., Droste, M., et al. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0997 · Cited by 56 · see citing works

Selective Glucocorticoid Receptor Antagonist CORT125281 Activates Brown Adipose Tissue and Alters Lipid Distribution in Male Mice

Kroon, J., Koorneef, L. L., van den Heuvel, J. K., Verzijl, C. R. C., van de Velde, N. M., Mol, I. M., Sips, H. C. M., Hunt, H., Rensen, P. C. N., & Meijer, O. C. (2017) · Endocrinology · doi:10.1210/en.2017-00512 · Cited by 52 · see citing works

Update on medical treatment for Cushing’s disease

Cuevas-Ramos, D., Lim, D., & Fleseriu, M. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0033-9 · Cited by 40 · see citing works

Mifepristone Treatment in Four Cases of Primary Bilateral Macronodular Adrenal Hyperplasia (BMAH)

Cohan, P., East, H. E., Galati, S.-J., Mercado, J. U., Lim, P. J., Lamerson, M., Smith, J. J., Peters, A. L., & Yuen, K. C. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02638 · Cited by 39 · see citing works

Cortisol measurement in patients receiving metyrapone therapy

Owen, L. J., Halsall, D. J., & Keevil, B. G. (2010) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2010.010167 · Cited by 37 · see citing works

Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults

Armani, S., Ting, L. S. L., Sauter, N. P., Darstein, C., Tripathi, A. P., Wang, L., Zhu, B. Y., Gu, H., Chun, D. Y., Einolf, H. J., et al. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0497-0 · Cited by 37 · see citing works

Structure–Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors

Papillon, J. P. N., Adams, C. M., Hu, Q., Lou, C., Singh, A. K., Zhang, C., Carvalho, J., Rajan, S., Amaral, A., Beil, M. E., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00407 · Cited by 36 · see citing works

Medical suppression of hypercortisolemia in Cushing’s syndrome with particular consideration of etomidate

Heyn, J., Geiger, C., Hinske, L. C., Briegel, J., & Weis, F. C. (2011) · Pituitary · doi:10.1007/s11102-011-0314-3 · Cited by 32 · see citing works

Sustained weight loss in patients treated with mifepristone for Cushing’s syndrome: a follow-up analysis of the SEISMIC study and long-term extension

Fein, H. G., Vaughan, T. B., Kushner, H., Cram, D., & Nguyen, D. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0059-5 · Cited by 32 · see citing works

Adding metyrapone to chemotherapy plus mitotane for Cushing’s syndrome due to advanced adrenocortical carcinoma

Claps, M., Cerri, S., Grisanti, S., Lazzari, B., Ferrari, V. D., Roca, E., Perotti, P., Terzolo, M., Sigala, S., & Berruti, A. (2017) · Endocrine · doi:10.1007/s12020-017-1428-9 · Cited by 31 · see citing works

Rational, Effective Metyrapone Treatment of ACTH-Independent Bilateral Macronodular Adrenocortical Hyperplasia (AIMAH).

Omori, N., Nomura, K., OMORI, K., Takano, K., & Obara, T. (2001) · Endocrine Journal · doi:10.1507/endocrj.48.665 · Cited by 30 · see citing works

Cushing's Syndrome: Where and How to Find It

Debono, M., & Newell-Price, J. D. C. (2016) · Frontiers of hormone research · doi:10.1159/000443861 · Cited by 30 · see citing works

Mifepristone Treatment for Mild Autonomous Cortisol Secretion Due to Adrenal Adenomas: A Pilot Study

Belokovskaya, R., Ravikumar, A., Arumugam, D., Izadmehr, S., Goddard, G. M., Geer, E. B., & Levine, A. C. (2019) · Endocrine Practice · doi:10.4158/ep-2019-0047 · Cited by 30 · see citing works

Medical therapy for Cushing’s disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers

Fleseriu, M., & Petersenn, S. (2015) · Pituitary · doi:10.1007/s11102-014-0627-0 · Cited by 29 · see citing works

Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus

SCHWARTZ, S., RENDELL, M., AHMANN, A., THOMAS, A., ARAUZPACHECO, C., & WELLES, B. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.05.021 · Cited by 29 · see citing works

Primary adrenal hypercortisolism: minimally invasive surgical treatment or medical therapy? A retrospective study with long-term follow-up evaluation

Guerrieri, M., Campagnacci, R., Patrizi, A., Romiti, C., Arnaldi, G., & Boscaro, M. (2010) · Surgical Endoscopy · doi:10.1007/s00464-010-1000-7 · Cited by 26 · see citing works

A successful case of pregnancy in a woman with ACTH-independent Cushing’s syndrome treated with ketoconazole and metyrapone

Zieleniewski, W., & Michalak, R. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1290070 · Cited by 24 · see citing works

Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension

Hoyt, S. B., Taylor, J., London, C., Ali, A., Ujjainwalla, F., Tata, J., Struthers, M. D., Cully, D. F., Wisniewski, T., Ren, N., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.04.021 · Cited by 24 · see citing works

Discovery of Novel Pyrazole-Based Selective Aldosterone Synthase (CYP11B2) Inhibitors: A New Template to Coordinate the Heme-Iron Motif of CYP11B2

Sakakibara, R., Sasaki, W., Onda, Y., Yamaguchi, M., Ushirogochi, H., Hiraga, Y., Kanako, S., Nishio, M., Egi, Y., Takedomi, K., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00328 · Cited by 24 · see citing works

Successful Long-Term Treatment of Cushing Disease with Mifepristone (RU486)

Basina, M., Liu, H., Hoffman, A. R., & Feldman, D. (2012) · Endocrine Practice · doi:10.4158/ep11391.cr · Cited by 23 · see citing works

Multiple salivary cortisol measurements are a useful tool to optimize metyrapone treatment in patients with Cushing's syndromes treatment: case presentations

Yoshida, K., Fukuoka, H., Odake, Y., Nakajima, S., Tachibana, M., Ito, J., Hosokawa, Y., Yamada, T., Miura, H., Suematsu, N., et al. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00375 · Cited by 23 · see citing works

Adrenal Surgery for Cushing’s Syndrome

Dalmazi, G. D., & Reincke, M. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.01.004 · Cited by 23 · see citing works

Preoperative treatment with metyrapone in patients with Cushing’s syndrome due to adrenal adenoma: a pilot prospective study

Puglisi, S., Perotti, P., Barbot, M., Cosio, P., Scaroni, C. M., Stigliano, A., Lardo, P., Morelli, V., Polledri, E., Chiodini, I., et al. (2018) · Endocrine Connections · doi:10.1530/ec-18-0400 · Cited by 22 · see citing works

A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome

Valassi, E., Aulinas, A., Glad, C. A. M., Johannsson, G., Ragnarsson, Ó., & Webb, S. M. (2017) · Clinical Endocrinology · doi:10.1111/cen.13414 · Cited by 21 · see citing works

Emerging drugs for Cushing’s disease

Guelho, D., & Grossman, A. B. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1047762 · Cited by 14 · see citing works

Effects of Mifepristone on Nonalcoholic Fatty Liver Disease in a Patient with a Cortisol-Secreting Adrenal Adenoma

Ragucci, E., Nguyen, D., Lamerson, M., & Moraitis, A. G. (2017) · Case Reports in Endocrinology · doi:10.1155/2017/6161348 · Cited by 14 · see citing works

Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in vivo activity

Meyers, K. M., Cogan, D. A., Burke, J., Arenas, R., Balestra, M., Brown, N. F., Chen, Z., Cerny, M. A., Clifford, H. E., Colombo, F., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.12.015 · Cited by 13 · see citing works

New and emerging drug therapies for Cushing’s disease

Störmann, S., & Schopohl, J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1504021 · Cited by 13 · see citing works

Role of Ketoconazole Treatment in Urinary-Free Cortisol-to-Cortisone and Tetrahydrocortisol-to-Tetrahydrocortisone Ratios in Nonectopic Cushing's Syndrome

Stiefel, P., Morillo, J. S. G., Jimenez, L., Pamies, E., Miranda, M. L., Ruiz, J. C., Villar, J. R., & Leal‐Cerro, A. (2002) · Endocrine · doi:10.1385/endo:18:3:279 · Cited by 9 · see citing works

Advances in the medical management of Cushing's syndrome

Giraldi, F. P., & Cavagnini, F. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.14.2423 · Cited by 9 · see citing works

Drifting of heme-coordinating group in imidazolylmethylxanthones leading to improved selective inhibition of CYP11B1

Gobbi, S., Hu, Q., Zimmer, C., Belluti, F., Rampa, A., Hartmann, R. W., & Bisi, A. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.078 · Cited by 8 · see citing works

No Postoperative Adrenal Insufficiency in a Patient with Unilateral Cortisol-Secreting Adenomas Treated with Mifepristone before Surgery

Saroka, R. M., Kane, M. P., Robinson, L. R., & Busch, R. S. (2016) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s39997 · Cited by 7 · see citing works

Primary bilateral adrenal nodular disease with Cushing's syndrome: varying aetiology

Jarial, K. D. S., Walia, R., Nahar, U., & Bhansali, A. K. (2017) · BMJ Case Reports · doi:10.1136/bcr-2017-220154 · Cited by 5 · see citing works

Etomidate and Cushing's syndrome

COSTA, J., RAMOS, D., MASSAVA, S., Carvalho, D. M., & Pignatelli, D. (1986) · Anaesthesia · doi:10.1111/j.1365-2044.1986.tb13187.x · Cited by 4 · see citing works

Glucocorticoid Receptor Antagonist Administration Prevents Adrenal Gland Atrophy in an ACTH-Independent Cushing’s Syndrome Rat Model

Yasuda, A., Seki, T., Kametani, Y., Koizumi, M., Kitajima, N., Oki, M., Seki, M., Kakuta, T., & Fukagawa, M. (2019) · International Journal of Endocrinology · doi:10.1155/2019/8708401 · Cited by 4 · see citing works

Intérêt du kétoconazole dans le traitement de la maladie de Cushing

Pascal, V., Denet, S., Weryha, G., Kaminsky, P., Leclère, J., & Hartemann, P. (1993) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(05)82527-5 · Cited by 3 · see citing works

Drug design strategies for Cushing’s syndrome

Usanov, S. A., Kliuchenovich, A. V., & Strushkevich, N. V. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1559146 · Cited by 3 · see citing works

[Ketoconazole in the control of arterial hypertension in Cushing's syndrome].

Romero, J. M. C., Perez, F. M., Barreiro, J. A. A., & de Madrid, J. D. P. (1999) · PubMed · Cited by 1 · see citing works

[Ketoconazole: a new treatment of Cushing syndrome].

Leal‐Cerro, A., Español, C. S., García‐Luna, P. P., & Jiménez, R. A. (1986) · PubMed · Cited by 1 · see citing works

Preoperative Ketoconazole Therapy for Primary Bilateral Adrenocorticotropic Hormone-Independent Macronodular Adrenal Hyperplasia Syndrome

Parthvi, R., John, G., & Mehra, S. (2017) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000549 · Cited by 1 · see citing works

Etomidate in Severe Cushing Syndrome: A Systematic Review

Muthukuda, D. T., Liyanarachchi, K., Jayawickreme, K. P., Mahesh, P. K. B., Ruwanga, V. G. D., Kumar, S., Subasinghe, C. J., & Newell-Price, J. D. C. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf039 · Cited by 21 · see citing works

Approach to the Patient with Subclinical Cushing’s Syndrome

Ivović, M., Marina, L., Šojat, A. S., Tančić‐Gajić, M., Arizanović, Z., Kendereški, A., & Vujović, S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200813134328 · Cited by 18 · see citing works

Establishment of a novel human fetal adrenal culture model that supports de novo and manipulated steroidogenesis

Melau, C., Nielsen, J. E., Perlman, S., Lundvall, L., Langhoff Thuesen, L., Juul Hare, K., Schou Hammerum, M., Frederiksen, H., Mitchell, R. T., Juul, A., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa852 · Cited by 16 · see citing works

Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome

Araujo-Castro, M., Lamas, C., Nowak, E., Newell-Price, J. D. C., Reincke, M., & Castinetti, F. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf042 · Cited by 15 · see citing works

The effects of selected inhibitors on human fetal adrenal steroidogenesis differs under basal and ACTH-stimulated conditions

Melau, C., Riis, M. L., Nielsen, J. E., Perlman, S., Lundvall, L., Thuesen, L. L., Hare, K. J., Hammerum, M. S., Mitchell, R. T., Frederiksen, H. W., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02080-8 · Cited by 13 · see citing works

Diurnal salivary cortisol profiles in patients with Cushing's syndrome

Braun, L. T., Vogel, F., Zopp, S., Rubinstein, G., Schilbach, K., Künzel, H., Beuschlein, F., & Reincke, M. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1719-5381 · Cited by 8 · see citing works

Biochemical Control in Cushing's Syndrome: Outcomes of the Treatment in a Large Single Center Cohort

Ritzel, K., Fazel, J., August, L., Fedtke, V., Nowak, E., Vogel, F., Braun, L., Zopp, S., Then, C., Kunzel, H. E., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae337 · Cited by 6 · see citing works

Advances in the medical management of hypercortisolism: current strategies, monitoring, and emerging therapies

Mosquera, J. E., Rahimi, L., & Hamidi, O. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000920 · Cited by 2 · see citing works

Levoketoconazole

McCartney, N. K., & Baker, D. E. (2022) · Hospital Pharmacy · doi:10.1177/00185787221115368 · Cited by 1 · see citing works

Molecular pathology of primary aldosteronism and hypercortisolism: Impact on adrenal surgery

Carling, T., Stratakis, C. A., Faucz, F. R., & Juhlin, C. C. (2026) · iScience · doi:10.1016/j.isci.2026.114910 · Cited by 1 · see citing works

Rare complication of cushing’s syndrome in the elderly: a case report

Li, C., Cao, G., Jin, F., & Ning, X. (2021) · Endocrine · doi:10.1007/s12020-021-02844-5

36/w mit Gesichtsschwellung und -rötung, Rückenschmerzen und Leukozytose

Lichtenauer, U. D. (2022) · Der Internist · doi:10.1007/s00108-022-01311-1

Novas abordagens terapêuticas na síndrome de Cushing

Fonseca, M. B. T., Takahashi, L. H., Moore, K., Borin, C. C. C., da Silva, A. C. R., Duarte, S. I. D. A., Pessoa, A. K. O., da Silva, M. B., Cotta, M. J. S. S., & do Sacramento, N. D. A. (2023) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e15055.2023

Advances in pharmacological treatment of Cushing's disease.

Chai, J., Tang, Y. J., Liu, Y., Tan, H., & Li, J. (2024) · PubMed Central · doi:10.11817/j.issn.1672-7347.2024.240306

Prise en charge anesthésiologique lors de chirurgie surrénalienne

Rey, A., Cruchon, K., Kopp, P. A., Luzuy‐Guarnero, V., Zingg, T., Blanc, C., & Albrecht, E. (2025) · EMC-Anesthésie réanimation/Encyclopédie médico-chirurgicale. Anesthésie, réanimation · doi:10.1016/s0246-0289(24)48414-4

Gestione anestesiologica durante la chirurgia surrenalica

Rey, A., Cruchon, K., Kopp, P. A., Luzuy‐Guarnero, V., Zingg, T., Blanc, C., & Albrecht, E. (2025) · EMC - Anestesia-Rianimazione · doi:10.1016/s1283-0771(25)50688-6

Manejo anestésico en la cirugía de las glándulas suprarrenales

Rey, A., Cruchon, K., Kopp, P. A., Luzuy‐Guarnero, V., Zingg, T., Blanc, C., & Albrecht, E. (2025) · EMC - Anestesia-Reanimación · doi:10.1016/s1280-4703(25)50631-x

Additional file 2 of The effects of selected inhibitors on human fetal adrenal steroidogenesis differs under basal and ACTH-stimulated conditions

Melau, C., Riis, M. L., Nielsen, J. E., Perlman, S., Lundvall, L., Thuesen, L. L., Hare, K. J., Hammerum, M. S., Mitchell, R. T., Frederiksen, H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16584675

Additional file 1 of The effects of selected inhibitors on human fetal adrenal steroidogenesis differs under basal and ACTH-stimulated conditions

Melau, C., Riis, M. L., Nielsen, J. E., Perlman, S., Lundvall, L., Thuesen, L. L., Hare, K. J., Hammerum, M. S., Mitchell, R. T., Frederiksen, H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16584672

Additional file 3 of The effects of selected inhibitors on human fetal adrenal steroidogenesis differs under basal and ACTH-stimulated conditions

Melau, C., Riis, M. L., Nielsen, J. E., Perlman, S., Lundvall, L., Thuesen, L. L., Hare, K. J., Hammerum, M. S., Mitchell, R. T., Frederiksen, H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16584678

Störungen des Cortisol-Haushaltes

Osswald-Kopp, A. (2026) · CME · doi:10.1007/s11298-026-4573-8

Medical Therapies in Cushing’s Syndrome

Tritos, N. A., & Biller, B. M. K. (2016) · Springer eBooks · doi:10.1007/978-3-319-45950-9_9 · Cited by 1 · see citing works

Medical therapy for Cushing’s disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers

Fleseriu, M., & Petersenn, S. (2015) · Pituitary · doi:10.1007/s11102-014-0627-0 · Cited by 29 · see citing works

Steroid Biosynthesis Inhibitors in the Therapy of Hypercortisolism: Theory and Practice

Igaz, P., Tömböl, Z., Szabó, P. M., Likó, I., & Rácz, K. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708786242921 · Cited by 55 · see citing works

Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome

Araujo-Castro, M., Lamas, C., Nowak, E., Newell-Price, J. D. C., Reincke, M., & Castinetti, F. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf042 · Cited by 15 · see citing works

Medical Therapy of Hypercortisolism

Feelders, R. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64356-8 · Cited by 2 · see citing works